Cardiogen

Key Benefits#

• Cardioprotective effects on myocardial tissue
• Normalization of cardiomyocyte protein synthesis
• May improve cardiac rhythm and conduction
• Support for recovery from ischemic cardiac events
• Anti-aging effects on heart tissue
• Potential reduction in cardiac fibrosis
• Often combined with Epithalon for comprehensive cardiovascular longevity support

Mechanism of Action#

Cardiogen acts as a gene expression modulator in cardiomyocytes. The tetrapeptide Ala-Glu-Asp-Arg penetrates cell nuclei and interacts with chromatin, modulating the expression of cardiac-specific proteins involved in contraction, energy metabolism, and cell survival. It normalizes protein synthesis in myocardial tissue, reduces apoptosis of cardiomyocytes, and may support cardiac muscle cell renewal. Its sequence is homologous to cardiac tissue proteins, providing organ specificity.

Dosing Protocols#

Side Effects#

• Generally well tolerated in available research
• Mild injection site reactions
• No significant adverse cardiovascular events reported at standard doses

Contraindications#

Not FDA approved. Not a substitute for standard cardiac medications. Use under medical supervision for any diagnosed cardiac condition.

Storage#

Store at 2–8°C. Protect from moisture and light.

1. 1.
   Echocardiographic Risk Stratification in Heart Failure with Post-Capillary Pulmonary Hypertension: Prognostic Value of LAVI and TAPSE/PASP

   Berthelot E, Bauer F, Fauvel C, Paclot M, Eicher JC, de Groote P et al. · European heart journal. Cardiovascular Imaging · 2026PubMed Verified

2. 2.
   Screening for transthyretin amyloid cardiomyopathy in patients with musculoskeletal symptoms: Red flags in the rheumatology/orthopedics practice setting

   Bardin T, Bigorre N, Hachulla E, Chapurlat R, Delbarre MA, Obert L et al. · Joint bone spine · 2025PubMed Verified

3. 3.
   SPARC: a structural pathogenicity algorithm for risk classification of hERG variants

   Chatelain FC, de Oliveira BR, Grataloup G, Robert N, Alameh M, Thollet A et al. · Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026PubMed Verified

4. 4.
   French consensus statement on transition of adolescent and young adults with rare pulmonary disease from paediatric to adult care: a Delphi method study

   Peulier-Maitre E, Goutaki M, Nathan N, Patout M, Amedro P, Beltramo G et al. · ERJ open research · 2025PubMed Verified

5. 5.
   Characteristics and Prognosis of Wild-Type Transthyretin Amyloid Cardiomyopathy Patients Diagnosed Before 65 Years Old

   Guijarro D, Eicher JC, Bézard M, Piriou N, Sauer F, Roubille F et al. · JACC. Advances · 2025PubMed Verified

6. 6.
   Reduced Native T1 Values of Wrist Tissues in Transthyretin Cardiac Amyloidosis

   Deux JF, Brugières P, Kharoubi M, Zaroui A, Oghina S, Damy T et al. · Journal of clinical medicine · 2025PubMed Verified

7. 7.
   The Healthcare Amyloidosis European Registry (HEAR): design of a national registry with a European extension strategy, and foundation of the F-CRIN GRACE network

   Réant P, Kharoubi M, Donal E, Bauer F, Bézard M, Bisson A et al. · Orphanet journal of rare diseases · 2025PubMed Verified

8. 8.
   Non-amyloid specific treatment for transthyretin cardiac amyloidosis: a clinical consensus statement of the ESC Heart Failure Association

   Garcia-Pavia P, Gonzalez-Lopez E, Anderson LJ, Cappelli F, Damy T, Fontana M et al. · European heart journal · 2026PubMed Verified

9. 9.
   Clinical care of family members of patients with dilated cardiomyopathy

   Verdonschot JAJ, Kaski JP, Asselbergs FW, Behr ER, Charron P, Dawson D et al. · European heart journal · 2025PubMed Verified

10. 10.
    Nonagenarian patients with ATTR cardiac amyloidosis: should they be treated with tafamidis?

    Jobbé-Duval A, Damy T, Broussier A · European heart journal · 2025PubMed Verified

11. 11.
    Diagnostic pathway for cardiac amyloidosis from the healthcare professional's perspective: results from the French DIAM-ATTR survey

    Oghina S, Legallois D, Hyafil F, Amara W, Andrès E, Bardin T et al. · Annals of medicine · 2025PubMed Verified

12. 12.
    Impact of Tafamidis on survival in elderly patients: Insights from the Healthcare European Amyloidosis Registry

    Jobbé-Duval A, Kharoubi M, Donal E, Bauer F, Broussier A, Bisson A et al. · International journal of cardiology · 2025PubMed Verified

13. 13.
    Men and women differ with regard to the prevalence, phenotype, and prognosis of wild-type transthyretin amyloid cardiomyopathy

    Zaroui A, Lafont C, Kharoubi M, Audureau E, Bézard M, Hentati M et al. · Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis · 2025PubMed Verified

14. 14.
    Cardiogenetics and uncertainty: Evaluation of professional vulnerability in France

    Gaudillat L, Patay L, Sawka C, Baurand A, Nambot S, Level C et al. · European journal of medical genetics · 2025PubMed Verified

15. 15.
    Study protocol for a multicenter randomized controlled trial on simulation-based communication training for pediatric cardiology trainees (SIMUL-CHD)

    Padovani P, Hauet Q, Lefort B, Chauviré-Drouard A, Letellier M, Bergé M et al. · BMC medical education · 2024Clinical TrialPubMed Verified

16. 16.
    Improving genetic testing pathways for transthyretin amyloidosis in France: challenges and strategies

    Hebrard B, Babonneau ML, Charron P, Consolino E, Dauriat B, Dupin-Deguine D et al. · Orphanet journal of rare diseases · 2024PubMed Verified

17. 17.
    A series of cases of transthyretin amyloid cardiomyopathy with negative bone scintigraphy but a confirmed positive endomyocardial biopsy

    Fraix A, Itti E, Zaroui A, Kharoubi M, Poullot E, Lerman L et al. · Orphanet journal of rare diseases · 2024PubMed Verified

18. 18.
    Combined daratumumab-pomalidomide and ultra-fractionated whole breast irradiation is safe!

    Debbi K, Loganadane G, Roulin L, Belhadj K, Boukhobza C, Saoudi A et al. · Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2024PubMed Verified

19. 19.
    Systematic analysis of SCN5A variants associated with inherited cardiac diseases

    Hermida A, Jedraszak G, Ader F, Denjoy I, Fressart V, Maury P et al. · Heart rhythm · 2025PubMed Verified

20. 20.
    Post-capillary pulmonary hypertension in heart failure: impact of current definition in the PH-HF multicentre study

    Fauvel C, Damy T, Berthelot E, Bauer F, Eicher JC, de Groote P et al. · European heart journal · 2024PubMed Verified

21. 21.
    Phenotype and prognostic factors in geriatric and non-geriatric patients with transthyretin cardiomyopathy

    Volpentesta E, Kharoubi M, Donadio C, Rebiai K, Fanen P, Funalot B et al. · ESC heart failure · 2024PubMed Verified

22. 22.
    Prevalence and phenotypes associated with ALPK3 null variants in a large French multicentric cohort: Confirming its involvement in hypertrophic cardiomyopathy

    Ader F, Jedraszak G, Janin A, Billon C, Buisson NR, Bloch A et al. · Clinical genetics · 2024PubMed Verified

23. 23.
    World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

    Brito D, Albrecht FC, de Arenaza DP, Bart N, Better N, Carvajal-Juarez I et al. · Global heart · 2023ReviewPubMed Verified

24. 24.
    Rubidium Chloride Rb 82

    2006ReviewPubMed Verified

25. 25.
    Clinical presentation of calmodulin mutations: the International Calmodulinopathy Registry

    Crotti L, Spazzolini C, Nyegaard M, Overgaard MT, Kotta MC, Dagradi F et al. · European heart journal · 2023PubMed Verified

26. 26.
    Comparison of cardiac involvement, extracardiac manifestations and outcomes between homozygote and heterozygote transthyretin p.Val142Ile (V122I) variant in patients with hereditary transthyretin amyloidosis: a cohort study

    Albenque G, Bézard M, Kharoubi M, Odouard S, Lunati A, Poullot E et al. · Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis · 2023PubMed Verified

27. 27.
    Amylo-AFFECT-QOL, a self-reported questionnaire to assess health-related quality of life and to determine the prognosis in cardiac amyloidosis

    Kharoubi M, Bézard M, Broussier A, Galat A, Gounot R, Poullot E et al. · Frontiers in cardiovascular medicine · 2023PubMed Verified

28. 28.
    Real-Life Evaluation of an Algorithm for the Diagnosis of Cardiac Amyloidosis

    Bézard M, Kharoubi M, Galat A, Le Bras F, Poullot E, Molinier-Frenkel V et al. · Mayo Clinic proceedings · 2023PubMed Verified

29. 29.
    Sequencing and titrating approach of therapy in heart failure with reduced ejection fraction following the 2021 European Society of Cardiology guidelines: an international cardiology survey

    Fauvel C, Bonnet G, Mullens W, Giraldo CIS, Mežnar AZ, Barasa A et al. · European journal of heart failure · 2023PubMed Verified

30. 30.
    Evaluation of a new ELISA assay for monoclonal free-light chain detection in patients with cardiac amyloidosis

    Abroud H, Beldi-Ferchiou A, Audard V, Lemonnier F, Le Bras F, Belhadj K et al. · EJHaem · 2022PubMed Verified

31. 31.
    Mass spectrometry-based proteomics in clinical practice amyloid typing: state-of-the-art from a French nationwide cohort

    Colombat M, Gaspard M, Camus M, Dalloux-Chioccioli J, Delas A, Poullot E et al. · Haematologica · 2022PubMed Verified

32. 32.
    Practical outpatient management of worsening chronic heart failure

    Girerd N, Mewton N, Tartière JM, Guijarro D, Jourdain P, Damy T et al. · European journal of heart failure · 2022ReviewPubMed Verified

33. 33.
    Amyloidosis from the patient perspective: the French daily impact of amyloidosis study

    Damy T, Adams D, Bridoux F, Grateau G, Planté-Bordeneuve V, Ghiron Y et al. · Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis · 2022PubMed Verified

34. 34.
    Prevalence and determinants of iron deficiency in cardiac amyloidosis

    Jobbé-Duval A, Bézard M, Moutereau S, Kharoubi M, Oghina S, Zaroui A et al. · ESC heart failure · 2022PubMed Verified

35. 35.
    Assessing Cardiac Amyloidosis Subtypes by Unsupervised Phenotype Clustering Analysis

    Bonnefous L, Kharoubi M, Bézard M, Oghina S, Le Bras F, Poullot E et al. · Journal of the American College of Cardiology · 2021PubMed Verified

36. 36.
    Prognostic Value of N-Terminal Pro-Brain Natriuretic Peptide and High-Sensitivity Troponin T Levels in the Natural History of Transthyretin Amyloid Cardiomyopathy and Their Evolution after Tafamidis Treatment

    Oghina S, Josse C, Bézard M, Kharoubi M, Delbarre MA, Eyharts D et al. · Journal of clinical medicine · 2021PubMed Verified

37. 37.
    History of extracardiac/cardiac events in cardiac amyloidosis: prevalence and time from initial onset to diagnosis

    Kharoubi M, Bézard M, Galat A, Le Bras F, Poullot E, Molinier-Frenkel V et al. · ESC heart failure · 2021PubMed Verified

38. 38.
    Mutation location and IKs regulation in the arrhythmic risk of long QT syndrome type 1: the importance of the KCNQ1 S6 region

    Schwartz PJ, Moreno C, Kotta MC, Pedrazzini M, Crotti L, Dagradi F et al. · European heart journal · 2021PubMed Verified

39. 39.
    Health-related quality of life and physical activity in children with inherited cardiac arrhythmia or inherited cardiomyopathy: the prospective multicentre controlled QUALIMYORYTHM study rationale, design and methods

    Amedro P, Werner O, Abassi H, Boisson A, Souilla L, Guillaumont S et al. · Health and quality of life outcomes · 2021Clinical TrialPubMed Verified

40. 40.
    Coronavirus disease vaccination in heart failure: No time to waste

    Roncalli J, Roubille F, Lamblin N, Girerd N, Mouquet F, Chapet N et al. · Archives of cardiovascular diseases · 2021PubMed Verified

41. 41.
    Prevalence and prognostic value of autonomic neuropathy assessed by Sudoscan® in transthyretin wild-type cardiac amyloidosis

    Kharoubi M, Roche F, Bézard M, Hupin D, Silva S, Oghina S et al. · ESC heart failure · 2021PubMed Verified

42. 42.
    Natural history and impact of treatment with tafamidis on major cardiovascular outcome-free survival time in a cohort of patients with transthyretin amyloidosis

    Bézard M, Kharoubi M, Galat A, Poullot E, Guendouz S, Fanen P et al. · European journal of heart failure · 2021PubMed Verified

43. 43.
    Rubidium-82 generator yield and efficiency for PET perfusion imaging: Comparison of two clinical systems

    Ahmadi A, Klein R, Lewin HC, Beanlands RSB, deKemp RA · Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2020PubMed Verified

44. 44.
    Psychosocial Impact of Predictive Genetic Testing in Hereditary Heart Diseases: The PREDICT Study

    Bordet C, Brice S, Maupain C, Gandjbakhch E, Isidor B, Palmyre A et al. · Journal of clinical medicine · 2020PubMed Verified

45. 45.
    Pharyngo-laryngeal involvement in systemic amyloidosis with cardiac involvement: a prospective observational study

    Bartier S, Bodez D, Kharoubi M, Canouï-Poitrine F, Chatelin V, Henrion C et al. · Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis · 2019PubMed Verified

46. 46.
    Secondary findings from next generation sequencing: Psychological and ethical issues. Family and patient perspectives

    Houdayer F, Putois O, Babonneau ML, Chaumet H, Joly L, Juif C et al. · European journal of medical genetics · 2019PubMed Verified

47. 47.
    Limitations of Rb-82 weight-adjusted dosing accuracy at low doses

    Moody JB, Hiller KM, Lee BC, Corbett JR, Ficaro EP, Murthy VL · Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2017PubMed Verified

48. 48.
    Significance of ST-segment deviation in patients with acute pulmonary embolism and negative T waves

    Zhan ZQ, Wang CQ, Wang ZX, Nikus KC, Baranchuk A, Yuan RX et al. · Cardiology journal · 2015PubMed Verified

49. 49.
    An Analysis of 3 Common CardioGen-82 82Rb Infusion System Injection Methods and Their Impact on Clinical Volume and Image Counts

    Roby AE, Johnson NP, Gould KL · Journal of nuclear medicine technology · 2015PubMed Verified

50. 50.
    2011 investigation of internal contamination with radioactive strontium following rubidium Rb 82 cardiac PET scan

    Pillai SK, Chang A, Murphy MW, Buzzell J, Ansari A, Whitcomb RC Jr et al. · Biosecurity and bioterrorism : biodefense strategy, practice, and science · 2014PubMed Verified